Vaishali Pharma Limited (VAISHALI.NS)
INR 12.45
(1.97%)
INR 12.45
(1.97%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 862.79 Million INR | 23.85% |
| 2022 | 696.62 Million INR | -2.62% |
| 2021 | 715.36 Million INR | 36.76% |
| 2020 | 523.07 Million INR | -10.45% |
| 2019 | 584.11 Million INR | -19.38% |
| 2018 | 724.55 Million INR | 10.62% |
| 2017 | 654.97 Million INR | -0.84% |
| 2016 | 660.54 Million INR | -0.98% |
| 2015 | 667.07 Million INR | -29.46% |
| 2014 | 945.6 Million INR | -21.66% |
| 2013 | 1.2 Billion INR | 1.6% |
| 2012 | 1.18 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 180.79 Million INR | -44.19% |
| 2023 Q2 | 125.65 Million INR | -6.39% |
| 2023 Q3 | 278.95 Million INR | 122.0% |
| 2023 Q4 | 323.96 Million INR | 16.13% |
| 2023 FY | 862.79 Million INR | 23.85% |
| 2023 Q1 | 134.22 Million INR | -49.93% |
| 2022 Q1 | 96.64 Million INR | -55.17% |
| 2022 Q2 | 131.59 Million INR | 36.16% |
| 2022 Q3 | 199.97 Million INR | 51.97% |
| 2022 Q4 | 268.09 Million INR | 34.06% |
| 2022 FY | 696.62 Million INR | -2.62% |
| 2021 FY | 715.36 Million INR | 36.76% |
| 2021 Q4 | 215.57 Million INR | -2.8% |
| 2021 Q3 | 221.79 Million INR | 11.67% |
| 2021 Q2 | 198.61 Million INR | 144.04% |
| 2021 Q1 | 81.38 Million INR | -54.09% |
| 2020 FY | 523.07 Million INR | -10.45% |
| 2020 Q4 | 177.27 Million INR | -16.64% |
| 2020 Q3 | 212.67 Million INR | 112.04% |
| 2020 Q2 | 100.29 Million INR | 190.19% |
| 2020 Q1 | 34.56 Million INR | -82.74% |
| 2019 Q1 | 181.97 Million INR | -34.37% |
| 2019 FY | 584.11 Million INR | -19.38% |
| 2019 Q4 | 200.29 Million INR | 96.86% |
| 2019 Q3 | 101.74 Million INR | -2.03% |
| 2019 Q2 | 103.85 Million INR | -42.93% |
| 2018 Q3 | 277.25 Million INR | 182.34% |
| 2018 Q2 | 98.19 Million INR | 0.0% |
| 2018 Q1 | 98.19 Million INR | -56.23% |
| 2018 FY | 724.55 Million INR | 10.62% |
| 2018 Q4 | 277.25 Million INR | 0.0% |
| 2017 Q3 | 224.35 Million INR | 95.99% |
| 2017 Q1 | 114.47 Million INR | 0.0% |
| 2017 Q2 | 114.47 Million INR | 0.0% |
| 2017 Q4 | 224.35 Million INR | 0.0% |
| 2017 FY | 654.97 Million INR | -0.84% |
| 2016 FY | 660.54 Million INR | -0.98% |
| 2015 FY | 667.07 Million INR | -29.46% |
| 2014 FY | 945.6 Million INR | -21.66% |
| 2013 FY | 1.2 Billion INR | 1.6% |
| 2012 FY | 1.18 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Hester Biosciences Limited | 3.04 Billion INR | 71.669% |
| RPG Life Sciences Limited | 5.82 Billion INR | 85.177% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 91.793% |
| Ipca Laboratories Limited | 77.05 Billion INR | 98.88% |
| Aarti Drugs Limited | 25.28 Billion INR | 96.588% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 95.248% |
| Albert David Limited | 3.62 Billion INR | 76.196% |
| Alembic Limited | 1.57 Billion INR | 45.214% |
| Alkem Laboratories Limited | 126.67 Billion INR | 99.319% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 98.588% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | 43.41% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 81.775% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -115.509% |
| Brooks Laboratories Limited | 794.86 Million INR | -8.547% |
| Eris Lifesciences Limited | 20.09 Billion INR | 95.706% |
| FDC Limited | 19.42 Billion INR | 95.559% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 96.221% |
| Gufic Biosciences Limited | 8.06 Billion INR | 89.304% |
| Hikal Limited | 17.84 Billion INR | 95.165% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 93.264% |
| Ind-Swift Limited | 5.02 Billion INR | 82.829% |
| Innova Captab Limited | 10.81 Billion INR | 92.021% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 95.955% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 58.659% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 98.713% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | 44.109% |
| Laurus Labs Limited | 50.01 Billion INR | 98.275% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 85.138% |
| Lupin Limited | 196.56 Billion INR | 99.561% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | 76.513% |
| Medico Remedies Limited | 1.44 Billion INR | 40.464% |
| Morepen Laboratories Limited | 17.01 Billion INR | 94.93% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 94.878% |
| Orchid Pharma Limited | 8.19 Billion INR | 89.47% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 92.506% |
| Sigachi Industries Limited | 3.98 Billion INR | 78.374% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 93.033% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.822% |
| Themis Medicare Limited | 3.81 Billion INR | 77.4% |
| Unichem Laboratories Limited | 16.57 Billion INR | 94.794% |
| Venus Remedies Limited | 5.91 Billion INR | 85.412% |
| Wanbury Limited | 5.75 Billion INR | 85.012% |
| Windlas Biotech Limited | 6.3 Billion INR | 86.326% |
| ZIM Laboratories Limited | 3.67 Billion INR | 76.524% |
| Sakar Healthcare Limited | 1.54 Billion INR | 44.035% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 99.703% |
| Divi's Laboratories Limited | 78.45 Billion INR | 98.9% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 93.34% |
| Mankind Pharma Limited | 103.34 Billion INR | 99.165% |
| Sequent Scientific Limited | 13.69 Billion INR | 93.701% |
| Neuland Laboratories Limited | 15.58 Billion INR | 94.464% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 97.497% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 99.27% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.546% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 79.517% |
| Wockhardt Limited | 27.89 Billion INR | 96.906% |
| Bal Pharma Limited | 3.39 Billion INR | 74.565% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.691% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 88.798% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | 9.787% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 94.854% |
| Shilpa Medicare Limited | 11.53 Billion INR | 92.518% |
| Valiant Laboratories Limited | 1.82 Billion INR | 52.608% |
| Ajanta Pharma Limited | 42.08 Billion INR | 97.95% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | 78.191% |
| Granules India Limited | 45.06 Billion INR | 98.085% |
| Medicamen Biotech Limited | 1.79 Billion INR | 51.881% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 66.719% |
| Piramal Enterprises Limited | 60.33 Billion INR | 98.57% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 99.186% |
| NATCO Pharma Limited | 40.02 Billion INR | 97.844% |
| Suven Life Sciences Limited | 116.92 Million INR | -637.881% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -71.117% |
| Strides Pharma Science Limited | 40.51 Billion INR | 97.87% |
| Indoco Remedies Limited | 18.17 Billion INR | 95.252% |
| Alpa Laboratories Limited | 1.08 Billion INR | 20.654% |
| Lasa Supergenerics Limited | 1.04 Billion INR | 17.305% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -14.209% |